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Abstract  15 
 16 
Remyelination is the regeneration of myelin sheaths following demyelination. This 17 
regenerative process is critical for the re-establishment of axonal conduction velocity and 18 
metabolic support to the axons.  Successful remyelination in the central nervous system (CNS) 19 
generally depends on the activation, proliferation and differentiation of oligodendrocyte 20 
progenitor cells (OPCs). However, other cell types play critical roles in establishing where a 21 
lesion is conducive for regeneration. In the last few years, several studies have described 22 
beneficial and detrimental roles played by astrocytes in remyelination.  This review will discuss 23 
recent developments in the concept of astrocyte reactivity, what is known about the astrocytic 24 
contribution to remyelination and highlight future avenues of investigation.   25 
 26 
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Myelin and the importance of remyelination 44 
In the CNS, myelin is generated by oligodendrocytes and is composed of lipid-rich, tightly 45 
overlapping membranous extensions which ensheath axons. This provides the axon with an 46 
insulating layer, increasing its resistance and decreasing its capacitance, thereby reducing radial 47 
loss of electrical current during the propagation of action potentials along the axon. As a result, 48 
action potentials only need to be actively regenerated at specialised high-density clusters of ion 49 
channels between segments known as nodes of Ranvier. Therefore, myelination of axons both 50 
greatly reduces the energy required and increases the speed with which axons can propagate 51 
action potentials per unit distance [1]. Monocarboxylate transporters on the oligodendrocyte cell 52 
membrane allow lactate transport to the axon, facilitating ATP production via oxidative 53 
phosphorylation [2].  54 
 55 
Unlike neurons, oligodendrocytes and their myelin sheaths can be regenerated following their 56 
loss, a process known as remyelination. Remyelination occurs in both animal models of 57 
demyelination and in humans with demyelinating diseases such as multiple sclerosis (MS) [3]. 58 
The regenerative response following demyelination often involves the generation of new 59 
oligodendrocytes and subsequent formation of new myelin sheaths. In contrast to most other 60 
neural cell types, new oligodendrocytes can be generated throughout life via the activation of a 61 
pool of tissue resident adult progenitor cells known as oligodendrocyte progenitor cells (OPCs). 62 
Upon demyelination, OPCs in the vicinity of the lesioned area become “activated” – an umbrella 63 
term for a series of changes which allow them to migrate to and proliferate within the lesion and 64 
differentiate into new mature oligodendrocytes.  Activation of OPCs involves, inter alia, the 65 
upregulation of transcription factors such as Sox2 and Tcf4, the former of which sustains 66 
proliferation with the latter being critical for differentiation [4-7]. The increased expression of 67 
growth factors within the lesion, such as fibroblast growth factor 2 (FGF2) and platelet-derived 68 
growth factor (PDGF), promotes the proliferation of OPCs, which differentiate into 69 
oligodendrocytes, expressing myelin genes in a manner dependent on the enhancer binding 70 
activity of myelin regulatory factor [8, 9].  These newly formed oligodendrocytes then ensheath 71 
demyelinated axons with new myelin [10, 11].  Although remyelination often occurs through the 72 
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proliferation and differentiation of OPCs into oligodendrocytes, two recent studies have 73 
indicated an alternative mechanism in which remyelination occurs via new process formation by 74 
existing oligodendrocytes [12, 13].  Relatively little is known yet about this form of remyelination, 75 
and in this review we will focus on the former, more thoroughly understood process of 76 
remyelination by differentiating OPCs.   77 
 78 
Many other cell types play key roles in regulating the process by which OPCs give rise to new 79 
remyelinating oligodendrocytes. Activated microglia and infiltrating monocyte-derived 80 
macrophages are essential for remyelination as they secrete important growth factors for OPC 81 
proliferation and differentiation as well as the phagocytic removal of remyelination-inhibiting 82 
myelin debris [14, 15].  In addition to the involvement of innate immunity, regulatory T cells, 83 
pericytes, and axons also influence remyelination [16-18].   84 
 85 
This article will review the recent literature examining the contribution of astrocytes to 86 
remyelination.  It will include an overview of the latest developments in astrocyte reactivity and 87 
polarisation, a discussion of the permissive and inhibitory roles played by astrocytes during 88 
remyelination, and highlight age-related changes in astrocyte function that may impact 89 
remyelination. We propose a model reconciling when the detriments of astrocytes may outweigh 90 
their benefits and outline potential therapeutic strategies to harness these cells for regeneration.   91 
 92 
Astrocyte development and phenotypic plasticity 93 
In mammals, astrocytes arise from radial glial cells in the ventricular zone [19].  In mice, this 94 
differentiation occurs at approximately embryonic day 12.5 in the mouse spinal cord and 95 
embryonic day 16 in the mouse brain in which migration and asymmetric proliferation produce 96 
clusters of immature astrocytes [19-21].  These immature astrocytes undergo a second wave of 97 
local symmetric proliferation to establish a mature population of astrocytes [19].  During 98 
development, astrocytes are critical for successful myelination, secreting several growth factors 99 
required for oligodendrogenesis [20].  In adulthood, astrocytes are regionally diverse, forming 100 
non-overlapping tiles within the CNS and are important for many homeostatic functions such as 101 
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synapse formation, synaptic pruning and modulation of neurotransmitters such as glutamate [22, 102 
23]. Additionally, they contribute to the formation and maintenance of the blood-brain barrier 103 
and provide glucose, lactate, and trophic factors to neurons [23]. They are also important for the 104 
brain’s clearance mechanisms, such as the glymphatic system [24, 25].  Histological markers of 105 
astrocytes include nestin, vimentin, glial fibrillary acidic protein (GFAP), the glutamate 106 
transporter GLAST, the calcium binding protein S100b, and aldehyde dehydrogenase 1 family, 107 
member L1 (Aldh1L1) [23].  All astrocytes express Aldh1L1, whereas only subsets of astrocytes 108 
express the other markers [23]. 109 
 110 
Astrocyte reactivity  111 
After injury to the CNS, astrocytes become reactive and upregulate cytoskeletal proteins such as 112 
GFAP and vimentin [22].  These reactive astrocytes, in which greater than one thousand genes 113 
are increased by more than twofold in mice, display cell body hypertrophy, upregulate various 114 
cytokines and chemokines, and can proliferate [26-28].  A study conducted in mice showed that 115 
this rapid response is transient, with most genes showing a decrease in expression within 1 week 116 
after injury [26].  Preventing the acute formation of reactive astrocytes in a traumatic injury 117 
mouse model results in greater axonal dieback, suggesting that the early formation of reactive 118 
astrocytes is neuroprotective and helps limit damage, if not directly supporting axonal 119 
regeneration [29].  The acute astrocyte response in demyelinating injuries can support myelin 120 
regeneration. For example, reactive astrocytes in acute MS lesions, many of which show some 121 
degree of remyelination, upregulate several remyelination-signalling factors [30]. However, in 122 
both traumatic and demyelinating injuries, reactive astrogliosis can evolve into the formation of 123 
a dense, complex and transcriptionally inactive astrocytic scar characterised by a dense 124 
meshwork of astrocytic processes with significant tissue reorganization that fails to resolve [22, 125 
30-32].  In neither traumatic nor demyelinating injury does the astrocytic scar support 126 
regeneration, but in the case of demyelinating injury it can be seen as the consequence of 127 
regeneration (remyelination) failure and not its cause.    128 
 129 
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Recent studies in mice have shown that the nature of the reactive astrocyte response depends 130 
on the initial stimulus [26, 33].  In a model of neuroinflammation, in which the bacterial endotoxin 131 
lipopolysaccharide (LPS) is administered, the formation of a neurotoxic astrocyte phenotype 132 
occurs which is dependent on LPS-stimulated microglia secreting tumour necrosis factor-a, 133 
complement component 1q (C1q), and interleukin-1a [33].  This astrocyte phenotype, which has 134 
been termed A1 (but see below discussion of controversies around this terminology), was shown 135 
to inhibit OPC proliferation and differentiation in addition to displaying toxicity to both neurons 136 
and oligodendrocytes.  In contrast, in a model  of ischemia, transcriptomic analysis demonstrates 137 
an astrocytic signature that appears neuroprotective [26].  This distinct transcriptional state, 138 
sometimes termed A2, is associated with the upregulation of genes encoding thrombospondins 139 
and neurotrophic factors [33].  Although this genetic signature suggests it might be pro-140 
regenerative, no studies so far (to our knowledge) have provided any functional evidence that 141 
this is the case.  An in-depth proteomic analysis of the secretome would be critical to validate 142 
these transcriptomic signatures [34]. Moreover, the ischemic cues resulting in the A2 phenotype 143 
are not yet defined, and it is not known whether this state arises in other physiological or 144 
pathological contexts. It is unknown what astrocytic state naturally arises following 145 
demyelination, in which myelin debris, apoptotic cell bodies, and damage associated molecular 146 
patterns may induce the activation of a unique astrocytic phenotype not yet described. Indeed, 147 
there is ongoing debate as to whether the two A1/A2 astrocyte phenotypes provide a full and 148 
accurate description of all reactive astrocytes, or whether they exist along a spectrum beyond 149 
the two A1/A2 states already described [22].  A recent study in mice, for instance, showed that 150 
activation of the unfolded protein response in astrocytes results in a neurotoxic state that is 151 
distinct from the A1 and A2 signatures [35].  Moreover, a study comparing the molecular 152 
signature of astrocytes in Huntington’s disease and two mouse models of Huntington’s disease 153 
did not find any evidence of an A1 astrocyte signature [36].  Instead, this group found a unique 154 
astrocyte molecular signature consisting of 62 genes in both the mouse models and the human 155 
specimens.  Furthermore, as the microglia response following demyelination in mice transitions 156 
from a pro-inflammatory to an immunoregulatory state, it  is unknown whether such a transition 157 
between states occurs in the astrocyte response to demyelination [15]. This transition in the 158 
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murine microglia population seems to be dependent on the necroptosis of the initial wave of pro-159 
inflammatory cells, inviting further questions on how this sequence of events may influence the 160 
reactive astrocyte population [37]. 161 
 162 
Astrocytes in demyelinating diseases 163 
Astrocytes are thought to play a major role in MS and especially in neuromyelitis optica (NMO) 164 
[38].  In MS, the astrocytic signature is dependent on the type of lesion [39].  In acute active 165 
lesions, there is an immune cell infiltration along with hypertrophic astrocytes expressing 166 
increased levels of GFAP and upregulation of several pro-inflammatory cytokines, chemokines as 167 
well as remyelination-signalling molecules [30, 40].  Remyelination is observed to variable 168 
degrees in acute active lesions, suggesting that the astrocyte response is favourable for 169 
remyelination in these types of lesions [9]. In contrast, inactive lesions are associated with a lower 170 
degree of inflammation with extensive demyelination and axonal loss.  Astrocytes observed in 171 
these lesions typically have small somata with long filamentous processes forming an astrocytic 172 
scar and are transcriptionally inactive [30, 38].  NMO is another demyelinating disease 173 
characterized by antibodies against the aquaporin 4 water channel present on astrocytes [41].  174 
This disease is characterized by astrocyte loss, immune cell infiltration, demyelination, and axonal 175 
degeneration. Loss of astrocytic endfeet on blood vessels leads to vascular permeability. In 176 
addition to MS and NMO, astrocytes have also been implicated in a variety of leukodystrophies, 177 
as has been extensively reviewed elsewhere [42]. 178 
 179 
Beneficial roles of astrocytes in remyelination 180 
Several studies over the last three decades have explored the role astrocytes play in models of 181 
remyelination and have shown that astrocytes can be both beneficial and detrimental to the 182 
remyelination process (Table 1; Figure 1).  One of the first studies to show a pro-remyelinating 183 
role for astrocytes was one in which astrocytes were transplanted into an ethidium bromide-184 
induced model of CNS demyelination in rats characterised by loss of astrocytes and extensive 185 
Schwann cell remyelination [43]. Following astrocyte transplantation, a significant increase in 186 
host oligodendrocyte remyelination was observed, suggesting the ability of astrocytes to 187 
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promote remyelination by these cells.  Subsequent to this study, it was found that the astrocytic 188 
expression of GFAP correlated with the expression of growth factors implicated in OPC 189 
maturation.  Astrocytes responding to demyelination in the rat spinal cord displayed a similar 190 
spatial and temporal profile as platelet-derived growth factor-A, fibroblast growth factor 2, 191 
transforming growth factor-b, and insulin-like growth factor-1 [44].  In this study, GFAP mRNA 192 
was associated with these growth factors in the recruitment phase of remyelination, whereas at 193 
later stages growth factor expression was coupled to areas with low GFAP mRNA expression.  In 194 
a more recent study using dietary cuprizone to induce demyelination in the mouse corpus 195 
callosum, it was found that astrocyte-derived tissue inhibitor of metalloproteinases-1 promoted 196 
remyelination [45]. 197 
 198 
In addition to the secretion of favourable factors for remyelination, astrocytes may also play a 199 
role in recruiting phagocytic microglia in areas of demyelination [46].  Myelin debris inhibits 200 
remyelination, and the clearance of myelin debris by phagocytic macrophages/microglia is 201 
essential for remyelination to proceed efficiently [47-49].  Inactivation of astrocytes in mice led 202 
to reduced myelin clearance following demyelination and a subsequent reduction in 203 
remyelination efficiency [46].   204 
 205 
Although not definitively shown in the context of remyelination, astrocytes are critical 206 
components of cholesterol metabolism and provide cholesterol to neurons.  As astrocytes are 207 
the major source of cholesterol and its CNS carrier, apolipoprotein E, it is feasible that astrocytes 208 
may also transfer cholesterol to maturing OPCs during a phase of remyelination where 209 
cholesterol would be critical for myelin synthesis [50].  Indeed, a recent study in mice examining 210 
the role of reverse cholesterol transport in macrophages/microglia implicates a role for 211 
cholesterol mobilisation within the demyelinated lesion [51]. 212 
 213 
Astrocytes and Schwann cell remyelination of the CNS 214 
In some regenerative contexts, CNS remyelination can also be performed by Schwann cells in 215 
addition to oligodendrocytes [52]. It was long thought that Schwann cells within CNS lesions were 216 
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derived from the adjacent peripheral nerve roots after a loss in the integrity of the glia limitans. 217 
However, genetic fate mapping in mice showed that the majority of remyelinating Schwann cells 218 
are derived from OPCs residing in the CNS [11, 52].  Although Schwann cell remyelination re-219 
establishes conduction velocity within axons in the CNS, it is not known whether Schwann cells 220 
can offer the metabolic support that oligodendrocytes normally provide to CNS axons [53].  It is 221 
also not well understood what molecular cues dictate the fate choice of OPCs.  There is evidence 222 
to suggest that astrocytes can influence whether OPCs differentiate into oligodendrocytes or 223 
Schwann cells in the context of injury (Table 1, Figure 1).  Transplantation of OPCs into X-224 
irradiated ethidium bromide lesions in rats that are devoid of astrocytes results in Schwann cell 225 
remyelination [54].  When OPCs are transplanted together with astrocytes, the appearance of 226 
Schwann cells is greatly reduced.  Similarly, engraftment of OPCs overexpressing an inhibitor of 227 
bone morphogenetic proteins (BMP) reduced Schwann cell differentiation, suggesting that 228 
astrocytes may be influencing fate choice partially through BMP inhibition.  Another study made 229 
use of a conditional astrocyte-specific pStat3 knockout mouse to prevent the formation of 230 
reactive astrocytes following demyelination [55].  Inactivation of reactive astrocytes resulted in 231 
a significantly greater degree of Schwann cell remyelination, supporting the hypothesis that 232 
astrocytes favour oligodendrocyte remyelination over Schwann cell remyelination [55].  233 
Furthermore, it was recently shown that OPCs in proximity to the vasculature in the absence of 234 
astrocytes are more likely to differentiate into Schwann cells [56].  This study found that 235 
astrocytes express the dual BMP/Wnt antagonist Socstdc1 and the lack thereof favours a 236 
Schwann cell fate choice by OPCs.  Revealing the molecular cues that lead to Schwann cell 237 
remyelination and its functional significance may lead to new therapeutic strategies to harness 238 
this cell type for CNS remyelination. 239 
 240 
Inhibitory roles of astrocytes in remyelination 241 
Some of the detrimental roles described for astrocytes is through secretion of inhibitory 242 
molecules and extracellular matrix components (Table 1; Figure 1).  After injury to the CNS, 243 
several cells including reactive astrocytes, microglia/macrophages and pericytes secrete 244 
extracellular matrix components [57].  Members of this extracellular matrix include the 245 
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chondroitin sulphate proteoglycans, hyaluronan, tenascin-C and fibronectin, all of which have 246 
been shown to inhibit remyelination and are present in lesions from MS patients [58].  Inhibiting 247 
the synthesis of chondroitin sulphate proteoglycans accelerates remyelination in a mouse model 248 
of demyelination [59].  Furthermore, a recent study conducted in both mice and rats described 249 
that the stiffness of the CNS increases with age and that this causes decreased OPC proliferation 250 
and differentiation [60].  In this study, when ageing OPCs were transplanted into young brains, 251 
they proliferated to a comparable extent as neonatal OPCs, while when young OPCs were 252 
transplanted into aged brains, their proliferation was significantly reduced.  It was further found 253 
that the mechanosensitive ion channel Piezo1 was a critical mediator of OPC response to 254 
substrate stiffness: silencing of the mechanosensitive channel Piezo1 in ageing OPCs resulted in 255 
the restoration of OPC proliferation and differentiation in the context of a stiffer substrate.  256 
Importantly, this study established that the age-related decline in OPC function is highly 257 
influenced by the extrinsic microenvironment.  Although not addressed in this study, the ageing 258 
astrocyte phenotype may be a critical contributor to the age-related increase in mechanical 259 
stiffness.  Indeed, some groups have reported an increase in astrocyte-associated extracellular 260 
matrix molecules with ageing in nonhuman primates, rats, and mice, such as hyaluronan and 261 
aggrecan, as well as reporting an increase in the expression of certain protease inhibitors [61-262 
64].  In addition to influencing the extracellular matrix, astrocytes express endothelin-1, a 263 
molecule which has been shown to be inhibitory to remyelination through notch activation in 264 
mice [65].  Astrocytes responding to endothelin-1 upregulate the Notch1 receptor ligand, jagged 265 
1, resulting in an inhibitory interaction between astrocytes and OPCs [65, 66].  266 
 267 
Beneficial or detrimental? 268 
It has been the convention to assign roles for astrocytes (and indeed other cells types) as being 269 
either beneficial or harmful. However, this is a rather binary view of what is likely to be a much 270 
subtler and complex reality that depends on the temporal and dynamic interplay between cells 271 
involved in remyelination. So, is it really helpful terminology? As remyelination is a tightly 272 
orchestrated sequence of events contingent on a multitude of cell types, astrocytes likely serve 273 
different functions at different stages of remyelination in synchrony with the other cell types.  274 
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Astrocytes potentially become detrimental when the timing and precision of this sequence of 275 
events is knocked out of synchrony, a concept we originally proposed as the ‘dysregulation 276 
hypothesis’ of remyelination failure (Box 1) [67].  Thus, what may appear to be detrimental may 277 
only be so in certain contexts. One such context where this precise control of remyelination could 278 
be dysregulated is ageing.  The following section will discuss the effect of ageing on remyelination 279 
and how the balance may be tipped towards a detrimental astrocytic phenotype.  280 
 281 
The effect of ageing on remyelination and astrocytes 282 
As with most other regenerative processes, remyelination efficiency declines with age [3, 68]; 283 
however, the endogenous mechanisms within glial cells which lead to this decline are still not 284 
well understood. Failure of remyelination is characteristic of the later stages of chronic 285 
demyelinating diseases, such as MS [69].  Indeed, lesions from chronic stages of MS often contain 286 
cells of the oligodendrocyte lineage which have failed to differentiate [70, 71].  Depending on 287 
age of onset, the progression of MS can involve a significant period of subclinical disease and a 288 
subsequent relapse remitting phase characterised by bouts of symptoms followed by recovery, 289 
reflecting the intrinsic ability of the younger brain to effectively regenerate lost myelin [69]. 290 
However, regardless of the age of onset, most patients transition to the progressive stage at 40-291 
45 years of age [72], which may reflect the remyelination efficiency declining below a critical 292 
point beyond which myelin is no longer being regenerated fast enough to prevent axon 293 
degeneration.   294 
 295 
Mouse and rat studies have shown that both OPC proliferation and differentiation become less 296 
efficient with age [73-75]. However, enhancing proliferation of OPCs does not lead to increased 297 
remyelination of lesions [76]. This led to the suggestion that the main bottleneck for OPCs in the 298 
remyelination response of the aged brain is their impaired ability to differentiate into functional 299 
oligodendrocytes [3].  Indeed, this reduced capacity of OPCs to differentiate and produce myelin 300 
is also observed during normal ageing [77, 78].  But non-cell autonomous mechanisms are also 301 
involved.  For example, macrophages exhibit an age-dependent decline in their ability to 302 
effectively clear myelin debris, both via phagocytosis [79, 80] and lysosomal degradation [81], 303 
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and ageing macrophages and microglia exhibit defective cytokine secretion following 304 
demyelinating injury [82].   305 
 306 
There are currently no studies (to our knowledge) which have directly investigated the ageing 307 
astrocyte response in the context of demyelination and remyelination.  However, several studies 308 
examining tissue from rodents, rhesus macaques, and humans have assessed the effects of 309 
normal ageing on the astrocyte population.  Most notably, ageing astrocytes appear more 310 
reactive, displaying an upregulation in cytoskeletal proteins associated with astrocytes 311 
responding to injury, in addition to displaying hypertrophic cell bodies with shorter processes 312 
[83-86].  In addition to these studies, recent investigations in mice have used RNA sequencing to 313 
examine the genetic changes that occur in astrocytes with ageing [87, 88].  Corroborating the 314 
morphological studies, these gene expression studies also show a shift in the astrocyte signature 315 
to a more reactive state, albeit with heterogeneity dependent on the CNS region analysed [87, 316 
88].  In addition to an upregulation in cytoskeletal protein genes such as GFAP, these studies 317 
noted an increase in genes associated with the complement components C3 and C4b.  These 318 
complement components are important for processes such as synapse elimination and have 319 
been implicated in age-related neuronal loss and several neurodegenerative diseases [89].  320 
Ageing astrocytes were also found to have a decrease in transcripts encoding cholesterol 321 
synthesis enzymes [87, 88] (Figure 2).  Given that cholesterol is important for myelin synthesis 322 
during remyelination, the decrease in enzymes regulating cholesterol synthesis would be 323 
predicted to have a negative effect during this regenerative process.  Overall, these studies 324 
suggest that like ageing microglia, ageing astrocytes may become more inflammatory, a state 325 
that has been termed “inflammaging” [82].  As mentioned above, however, future studies should 326 
examine the astrocyte secretome over the lifespan of the organism to validate many of the 327 
transcriptomic changes identified in these studies.  As astrocytes significantly modulate the 328 
various niches they occupy within the CNS through the secretion of various classes of molecules, 329 
identifying how these secreted products change with age will undoubtedly uncover new targets 330 
that might be harnessed to provide new therapeutic avenues.  Future studies using models of 331 
demyelination and remyelination are required to directly examine how the ageing astrocyte 332 
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response influences this regenerative process.  Given that ageing microglia are primed to be more 333 
pro-inflammatory after demyelination, it seems plausible that astrocytes may undergo a similar 334 
process, potentially contributing to greater tissue injury and reduced repair.   335 
 336 
Harnessing astrocytes to promote remyelination  337 
Several groups have conducted drug screens to identify clinically-approved medications that can 338 
directly enhance OPC differentiation to promote remyelination [90-92].  Although such screens 339 
have resulted in several promising compounds, the approach does not take into account the 340 
inhibitory nature of the lesion microenvironment or the effect of ageing.  In fact, when several of 341 
these medications are added to ageing OPCs or to OPCs plated on CSPGS, they are unable to 342 
enhance OPC maturation [59, 74].  It is, therefore, critical to take the ageing microenvironment 343 
into account when attempting to enhance remyelination.  As astrocytes are essential 344 
components of the lesion microenvironment, therapeutic strategies which target astrocyte 345 
function offer additional opportunities to promote remyelination. Since astrocytes are secretory 346 
cells, one approach may be to target various aspects of the astrocytic secretome.  For instance, 347 
pharmacological inhibition of CSPG synthesis accelerated remyelination in a focal demyelination 348 
model in young adult mice [59].  Another approach is to neutralise the effect of astrocyte-derived 349 
endothlin-1 by administering a pharmacological antagonist against the endothelin receptor [65].  350 
This strategy also resulted in accelerated remyelination in young adult mice subject to lysolecithin 351 
demyelination.  As Stat3 signalling in astrocytes promotes trophic support, targeting this pathway 352 
may be a feasible approach in the ageing context, where it was shown in rats a delay in growth 353 
factor production [22, 68, 93].  A deeper understanding of the ageing astrocyte response in 354 
remyelination will most likely reveal further therapeutic targets to enhance remyelination. 355 
 356 
Concluding remarks 357 
Astrocytes play a critical role in supporting remyelination.  Activated astrocytes secrete several 358 
growth factors important for OPC proliferation and differentiation, and they signal to microglia 359 
to clear myelin debris.  As astrocytes provide cholesterol to neurons, they may also be an 360 
important source of cholesterol for maturing OPCs.  Despite these benefits, astrocytes have also 361 
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been associated with the secretion of factors which inhibit remyelination such as several 362 
extracellular matrix molecules.  As remyelination is a tightly regulated process influenced by 363 
several cell types, astrocytes likely serve different roles at different stages to allow remyelination 364 
to proceed efficiently.  Dysregulation of this sequence of events leads to remyelination failure 365 
and is likely influenced by an astrocyte phenotype that is more detrimental than beneficial.  The 366 
ageing CNS is an example where remyelination becomes dysregulated. Addressing how the 367 
ageing astrocyte responds to demyelination may reveal new therapeutic targets to enhance 368 
remyelination in this context (see Outstanding Questions). 369 
 370 
Box 1 – Reconciling the differing roles of astrocytes in remyelination 371 
 372 
Astrocytes have been shown to be both beneficial and detrimental in remyelination. What 373 
determines when these cells are permissive or inhibitory? One hypothesis is the ‘dysregulation 374 
hypothesis’ [67].  As remyelination proceeds efficiently in the young CNS, reactive astrocytes are 375 
presumably beneficial to the process through the secretion of both permissive and inhibitory 376 
factors at different stages in a tightly regulated sequence of events. Moreover, the timely 377 
interaction of reactive astrocytes with other cells such as microglia and infiltrating macrophages 378 
is critical in establishing a microenvironment that is conducive for OPC proliferation and 379 
differentiation. As remyelination starts with the sufficient proliferation of OPCs to provide 380 
enough oligodendrocytes for myelin regeneration, it is important that mitogens and 381 
differentiation inhibitors would be upregulated in this first stage.  Indeed, reactive astrocytes and 382 
macrophages/microglia are a major source of these molecules. Once enough OPCs have 383 
proliferated to allow for a sufficient number of oligodendrocytes to be produced, differentiation 384 
inhibitors are suppressed and instead molecules that promote differentiation are upregulated.  385 
An example of such a factor is activin-A, a molecule secreted by immunoregulatory microglia at 386 
the onset of differentiation following the initial peak of pro-inflammatory cells [15].  387 
Furthermore, as both pro- and anti-inflammatory microglial factors such as tumour necrosis 388 
factor-a, complement component 1q (C1q), interleukin-1a,  nitric oxide, extracellular vesicles, 389 
and other molecules influence astrocyte polarization as well as survival, it is conceivable that the 390 
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astrocytic phenotypic state may change as a consequence of microglia polarization [33, 94-98].  391 
Remyelination likely fails when this tightly regulated process and intercellular interaction 392 
becomes dysregulated.  Such an instance where this occurs is during ageing, where several cells 393 
in the microenvironment become senescent and dysfunctional. The age-related delay in 394 
macrophage/microglia recruitment, growth factor secretion, and phagocytosis not only delays 395 
the OPC response, but also likely alters the reactive astrocyte response [48, 80, 93, 99, 100].  396 
Furthermore, as ageing microglia have a propensity to be more pro-inflammatory, they likely also 397 
promote a reactive astrocyte phenotype that is more pro-inflammatory, tipping the balance of 398 
when astrocytes are toxic rather than regenerative [87, 101]. According to the dysregulation 399 
hypothesis, it is in this context when normal permissive or inhibitory cues important for efficient 400 
remyelination become unsynchronised, resulting in cells appearing more detrimental than 401 
beneficial.  402 
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Figure Legends 632 
 633 
Figure 1. Astrocytes secrete several factors that either promote or inhibit remyelination.  634 
Astrocytes have been characterized to secrete several factors that are important for the 635 
proliferation of oligodendrocyte progenitor cells (OPCs), including the growth factors platelet-636 
derived growth factor-AA (PDGF-AA) and fibroblast growth factor 2 (FGF2), as well as the 637 
cytokines interleukin-1b (IL-1b) and tumor necrosis factor (TNF).  Astrocytes also promote OPC 638 
differentiation by producing ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor 639 
(BDNF), leukemia inhibitory factor (LIF), insulin-like growth factor-1 (IGF-1), CXCL1, and tissue 640 
inhibitor of metalloprotese-1 (TIMP-1).  Astrocytes are known to be involved in cholesterol 641 
metabolism of neurons and other CNS cell types, but it remains to be tested whether astrocytic 642 
production of cholesterol positively impacts myelin synthesis in remyelinating oligodendrocytes.  643 
Astrocytes also produce inhibitory molecules such as chondroitin sulphate proteoglycans 644 
(CSPGs), hyaluronan, endothelin-1 (ET-1), fibronectin, tenascin-c, and jagged-1.  Furthermore, 645 
astrocytes suppress Schwann cell differentiation from OPCs through the production of Socstdc1.  646 
Astrocytes also recruit monocytes through the production of CCL2 and microglia through the 647 
secretion of CXCL10.  648 
 649 
Figure 2. Ageing modulates the astrocyte phenotype and may contribute to the age-related 650 
decrease in remyelination efficiency.  Ageing has been shown to modulate the astrocyte 651 
phenotype in various ways. Ageing astrocytes display an altered morphology (top schematic).  652 
Genomic analyses of ageing astrocytes display an upregulation of several markers characteristic 653 
of a pro-inflammatory astrocyte phenotype, including glial fibrillary acidic protein (GFAP), serine 654 
protease inhibitor 3n (Serpina3n), complement components C3 and C4b, the chemokine Cxcl10, 655 
and molecules involved in antigen presentation (H2-D1, H2-K1).  Ageing astrocytes display a 656 
downregulation of genes associated with mitochondrial function and energy production (Ucp2, 657 
Cox8b, Atp5g1), antioxidant defence-related genes (Gpx8, Atox1), as well as cholesterol synthesis 658 
genes (Hmgcr).  Furthermore, ageing decreases the efficiency of remyelination, and it is possible 659 
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that a detrimental ageing astrocyte phenotype contributes to this reduction in remyelination 660 
capacity.  661 
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Permissive roles of astrocytes in remyelination 
Function Experiment Reference 




Transplantation of astrocytes into ethidium 
bromide-induced lesions in the rat spinal cord 
[43] 
Source of PDGF-A, FGF-2, 
TGF-B, and IGF-1 to 
promote OPC maturation 
Spatial and temporal examination of mRNA 
expression of growth factors following focal 
lysolecithin demyelination in the rat spinal cord 
[44] 
Recruit microglia to clear 
inhibitory myelin debris 
Astrocyte ablation using GFAP-TK mice in 
cuprizone-induced demyelination of the corpus 
callosum 
[46] 
Source of TIMP-1 to promote 
remyelination 
TIMP-1 KO mice in cuprizone-induced 
demyelination of the corpus callosum 
[45] 
 
Inhibitory roles of astrocytes in remyelination 
Function Experiment Reference 
Source of ET-1 to inhibit 
remyelination 
Astrocyte-specific knockout of ET-1 in the 
spinal cord of mice injected with lysolecithin 
[65]  
Secretion of inhibitory 
CSPGs 
Pharmacological inhibition of CSPG synthesis 
in lysolecithin-induced demyelination of the 
mouse spinal cord 
[59] 
Production of fibronectin 
aggregates 
Injection of astrocyte-derived fibronectin 
aggregates into lysolecithin-induced lesions of 
the rat 
[102]  
Source of inhibitory HMW 
hyaluronan 
Injection of HMW hyaluronan into 
lysolecithin-induced lesions of the mouse 
corpus callosum 
[103] 
Secretion of molecules which 
are toxic to oligodendrocytes 
Conditioned media taken from astrocytes 
stimulated by LPS-activated microglia 
[33] 
Abbreviations:  PDGF-A, platelet-derived growth factor-A; FGF-2, fibroblast growth factor-2; 
TGF-B, transforming growth factor-B; IGF-1, insulin-like growth factor-1; GFAP, glial 
fibrillary acidic protein; TK, thymidine kinase; TIMP-1, tissue inhibitor of metalloproteinases-
1; KO, knock-out; ET-1, endothelin-1; CSPGs, chondroitin sulphate proteoglycans; HMW, 
high molecular weight; LPS, lipopolysaccharide 
